Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic Therapy.

NCT03422068 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03422068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03422068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic Therapy.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2018
Completion date
July 10, 2019
Enrollment
15 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis